CYLD and non-small cell lung carcinoma: Several studies show that miR-454 functions as an oncogene in colorectal cancer [50], hepatocellular carcinoma [51], non-small cell lung cancer [52] and induce the oxaliplatin resistance in gastric carcinoma cells by targeting CYLD [53].